DDInter743 DDInter1376
Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. It has been demonstrated as an efficacious treatment for vaginal yeast infections in one single dose.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Fluconazole {u} (Compound) binds {v} (Gene) CYP3A7
Fluconazole {u} (Compound) upregulates {v} (Gene) MELK
Fluconazole {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C9 Inhibitors
Fluconazole {u} (Compound) downregulates {v} (Gene) WFS1
Fluconazole {u} (Compound) causes {v} (Side Effect) Rigors
Fluconazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ulipristal
Fluconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apalutamide
Fluconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abarelix
Fluconazole {u} may lead to a major life threatening interaction when taken with {v} Ivacaftor
Fluconazole {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Voriconazole
Fluconazole (Compound) binds CYP3A7 (Gene)
Fluconazole (Compound) upregulates MELK (Gene)
Fluconazole (Compound) is included by Cytochrome P450 2C9 Inhibitors (Pharmacologic Class)
Fluconazole (Compound) downregulates WFS1 (Gene)
Fluconazole (Compound) causes Rigors (Side Effect)
Fluconazole may cause a minor interaction that can limit clinical effects when taken with Ulipristal
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Abarelix
Fluconazole may lead to a major life threatening interaction when taken with Ivacaftor
Fluconazole (Compound) resembles Voriconazole (Compound) and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole